一、 通过分配方案的股东大会届次和日期 本次利润分配方案经上海艾力斯医药科技股份有限公司（以下简称"公司" 或"本公司"）2025 年 5 月 14 日的2024年年度股东大会授权公司董事会制定实施， 并经公司第二届董事会第十五次会议审议通过，具体情况如下： 证券代码：688578 证券简称：艾力斯 公告编号：2025-021 上海艾力斯医药科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.40元（含税） 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/9 | 2025/9/10 | 2025/9/10 | 2025 年 5 月 14 日，公司召开 2024 年年度股东大会，审议通过《关于提请股 东大会授权董事会进行 2025 年中期分红的议案》，在符合利润分配的条件下制定 具体的 2025 年上半年利润分配方案，并由董事会及其授权人士具体执行相关利润 分配方案，授权 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 0.39% during the reporting period, ranking 26th among 31 primary industries, underperforming the CSI 300 index which rose by 7.01% [4][14] - The industry shows resilience despite a slight decline in overall revenue and net profit for A-share pharmaceutical companies in the first half of the year, with stable gross profit margins [6] - The CXO sector has returned to high prosperity with significant growth in performance, while the chemical preparation sector shows a mixed performance [6] - The report highlights the approval of several innovative drugs, including Novartis' "Acrux" for IgA nephropathy and the first oral HER2 inhibitor "Zongertinib" by Boehringer Ingelheim [5][41] Industry Review - The pharmaceutical and biotechnology industry PE (TTM, excluding negative values) is at 31.41x, slightly down from 31.38x in the previous period, indicating a valuation below the average [20] - The top three sub-industries by PE are vaccines (56.18x), hospitals (42.24x), and medical devices (40.66x), while pharmaceutical circulation has the lowest valuation at 14.06x [20] - In the reporting period, 29 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 1 billion CNY [4] Important Industry News - The CDE released a draft guideline for single-arm clinical trials to support the regular approval of anti-tumor drugs [25] - Novartis' IgA nephropathy drug "Acrux" received NMPA approval, marking it as the first of its kind in China [28] - The approval of the new generation ALK inhibitor "Dirocitinib" by Xuan Bamboo Biotech for treating ALK-positive non-small cell lung cancer [36] - The approval of the ADC "Datopotamab deruxtecan" for treating HR-positive, HER2-negative breast cancer [39] Investment Recommendations - The report suggests focusing on investment opportunities in the chemical preparation sector, particularly innovative drugs, and the CXO sector due to their clear long-term growth logic [6]

9月2日，艾力斯大宗交易成交52万股，成交额5455.32万元，占当日总成交额的4.03%，成交价104.91 元，较市场收盘价115.29元折价9%。 | 交易日期 | 恒辨國核 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入管业部 | | 英出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-02 | 艾力斯 | 688578 | 104.91 | 2622.75 | 25 | 杭构专用 | 中信证券股份有限 公司上海分公司 | ਨੂੰ | | 2025-09-02 | 艾力斯 | 688578 | 104.91 | 1049.1 | 10 | 华夏证券股份有限 公司上海黄浦区黄 降幅度压处器不管 | 中信证券股份有限 公司上海分公司 | KA | | 2025-09-02 | 艾力斯 | 688578 | GMACAGA 104.91 | 1270 201 839.28 | 8 | 因奏清通证券股份 有限公司总部 | 中信证券股份有限 公司上海分公司 | ਨੂੰ | ...

Group 1: Core Insights - The recent approval of Jinfang Pharmaceutical's IPO marks a significant milestone for the Hong Kong innovative drug market, indicating an expansion of the 18A gate for new listings [1] - Jinfang Pharmaceutical focuses on KRAS mutations, particularly the KRAS G12C inhibitor, Fulzerasib, which is gaining attention in the market [1][5] - The global KRAS G12C inhibitor market is projected to grow from $489 million in 2024 to $3.491 billion by 2033, with a compound annual growth rate (CAGR) of 24.4% [3] Group 2: KRAS Market Dynamics - KRAS mutations account for approximately 14% of all cancer cases, with pancreatic cancer (88%), colorectal adenocarcinoma (50%), and lung adenocarcinoma (32%) being the most affected types [1] - The first KRAS G12C inhibitor, Sotorasib, had disappointing sales of $350 million in 2024, indicating challenges in market penetration [2][3] - Mirati Therapeutics' Adagrasib, another KRAS G12C inhibitor, is also underperforming with projected sales of $118 million in 2024 [3] Group 3: Fulzerasib's Potential - Fulzerasib has shown promising results in clinical trials for non-small cell lung cancer (NSCLC), achieving a confirmed overall response rate (cORR) of 49.1% [5][11] - The drug is positioned as a strong competitor in the KRAS G12C inhibitor market, potentially surpassing the first-in-class Sotorasib [11] - Fulzerasib is also expanding its indications to colorectal cancer, where it has demonstrated a cORR of 44.6% in early trials [9][11] Group 4: Business Development and Financials - Jinfang Pharmaceutical has secured significant partnerships, including a global exclusive licensing agreement with Innovent Biologics for Fulzerasib, which included upfront payments totaling $8.5 million [12] - The company has also engaged in collaborations for other pipelines, such as the KRAS G12D inhibitor GFH375, which has shown promising early clinical data [13][14] - Despite the potential of its lead product, the overall market for KRAS inhibitors remains underwhelming, necessitating further development and market strategies [11][15]

【跟踪牛人动态】超3000名"专业选手"如何调仓？榜首总收益超120% 单只标的浮盈超200% 【头条要闻】 9月第一天，为期一年的个人消费贷款财政贴息政策正式实施！ 无论你是计划换一部新手机、购置家用汽车，还是安排一次家庭旅行、装修新房，只要是通过正规渠道 申请消费贷款并真实用于消费，就有机会享受年化1个百分点的贴息"国补"。 王毅介绍上合组织天津峰会八大成果 2025年9月1日，上合组织天津峰会结束之际，中共中央政治局委员、外交部长王毅在峰会新闻中心同上 合组织秘书长叶尔梅克巴耶夫共同会见中外记者并答问。王毅介绍了本届峰会取得的八大成果。 海外中国股票ETF，规模大增 8月以来，中国资产持续获得全球资金"扫货"。多只海外上市的中国ETF规模激增，中国海外互联网 ETF-KraneShares的规模更是突破85亿美元。另据高盛统计，近一周中国内地股票基金吸金超40亿美 元，在新兴市场中遥遥领先。 站在当下时点，多家外资机构表示，在估值优势叠加技术实力的推动下，中国科技资产正成为全球投资 组合中不可或缺的战略板块，从而吸引资金持续涌入。 9月初公开市场到期规模大增 资金面仍有望平稳运行 9月初，公开市场资金到 ...

Core Viewpoint - Shanghai Ailis Pharmaceutical Technology Co., Ltd. announced a change in shareholder equity that has crossed the 1% threshold due to a reduction in shareholding by major shareholders [1][2]. Group 1: Shareholder Equity Changes - Shareholders Shanghai Aixiang Enterprise Development Center (Limited Partnership) and Nantong Aiyun Enterprise Development Center (Limited Partnership) reduced their combined shareholding from 53.05% to 51.87% after selling 5,316,500 shares on September 1, 2025 [2]. - The specific share reduction included 4,231,726 shares sold by Shanghai Aixiang and 1,084,774 shares sold by Nantong Aiyun [2]. Group 2: Shareholding Structure - After the reduction, the shareholding structure is as follows: - Shanghai Aixiang: 23,340,850 shares (51.87%) - Nantong Aiyun: 8,685,588 shares (1.93%) [2]. - The remaining shareholders, including Du Jinhao, Shanghai Qiaoke Enterprise Development Co., Ltd., Jeffrey Yang Guo, and Jennifer Guo, did not change their holdings [2]. Group 3: Compliance and Future Plans - The company confirmed that the reduction does not trigger mandatory tender offer obligations and will not affect the control or governance structure of the company [2]. - The shareholders have committed to continue adhering to relevant laws and regulations and will fulfill subsequent information disclosure obligations [2].

Core Viewpoint - The article reports on the significant trading activity of Ailis on September 1, highlighting a total of 30 transactions with a volume of 5.3165 million shares and a transaction value of 566 million yuan, indicating a discount of 9% compared to the closing price of the day [2][3][4]. Trading Activity Summary - On September 1, Ailis had a total trading volume of 5.3165 million shares, amounting to 566 million yuan, with a transaction price of 106.45 yuan per share, reflecting a 9% discount from the closing price [2][3]. - Institutional trading desks participated in 12 of the transactions, contributing a total of 383 million yuan in net purchases [2]. - Over the past three months, Ailis has recorded 33 transactions with a cumulative transaction value of 573 million yuan [2]. Stock Performance Summary - Ailis closed at 116.98 yuan on the reporting day, marking a 2.61% increase, with a daily turnover rate of 3.22% and a total trading volume of 1.705 billion yuan [2]. - The stock has seen a cumulative increase of 24.74% over the past five days, despite a net outflow of 356 million yuan in funds during the same period [2]. - The latest margin financing balance for Ailis stands at 852 million yuan, with an increase of 31.229 million yuan over the past five days, representing a growth rate of 3.81% [2].

Summary of Key Points Core Viewpoint - On September 1, a total of 14 stocks on the Sci-Tech Innovation Board (STAR Market) experienced block trading, with a cumulative transaction amount of 1.009 billion yuan [1]. Group 1: Trading Overview - There were 54 block trades executed, with a total trading volume of 10.0675 million shares [1]. - The stock with the highest transaction amount was Ailis, with 30 block trades totaling 531.65 thousand shares and a transaction amount of 566 million yuan [1]. - Other notable stocks in terms of transaction amounts included Haiguang Information and Dameng Data, with transaction amounts of 261 million yuan and 46.4 million yuan, respectively [1]. Group 2: Price and Performance Analysis - The average discount rates for block trades relative to the closing prices were highest for Delong Laser, Dameng Data, and Wukuang New Energy, with discount rates of 17.79%, 16.49%, and 12.17% respectively [1]. - The STAR 50 Index rose by 1.18% on the same day, with 358 stocks (61.20%) on the STAR Market experiencing price increases [1]. - The average increase for stocks involved in block trading was 2.24%, with the largest gains seen in Huahong Company, Haiguang Information, and Aibo Medical, which rose by 9.18%, 7.42%, and 4.27% respectively [1]. Group 3: Institutional Participation - Among the block trades, there were 17 transactions involving institutional buyers or sellers across 5 stocks, with the highest buying amounts in Ailis, Haiguang Information, and Huahong Company, totaling 383 million yuan, 261 million yuan, and 22.08 million yuan respectively [2]. - In terms of capital flow, 8 stocks saw net inflows from major funds, with Haiguang Information, Hanwujing, and Delong Laser leading with net inflows of 685 million yuan, 116 million yuan, and 18.64 million yuan respectively [2]. - Conversely, the stocks with the highest net outflows included Huahong Company, Ailis, and Dameng Data, with net outflows of 1.09 billion yuan, 136 million yuan, and 51.46 million yuan respectively [2].

Group 1: Core Views - The article highlights the recent movements of prominent fund managers in the public fund sector, focusing on their investment strategies and stock adjustments in response to market conditions [1][4][5]. Group 2: Zhang Kun's Strategy - Zhang Kun has reduced his holdings in Meituan by 46.43% while increasing his position in Beike, indicating a shift towards domestic demand logic [1][3]. - The E Fund Blue Chip Select Fund, managed by Zhang Kun, has a current size of 34.943 billion and a year-to-date return of 12.85% [3]. - The fund's hidden heavyweights include Focus Media and Meituan, with Focus Media's holdings increasing by 13.76% [3]. - Zhang Kun believes that the current pessimism regarding domestic demand is unfounded and anticipates a positive feedback loop in domestic consumption [4]. Group 3: Ge Lan's Focus - Ge Lan's China Europe Medical Health Fund has achieved a year-to-date return of 28.82%, with significant investments in the innovative drug sector [5][6]. - The fund's hidden heavyweights include Huadong Medicine and Zai Lab, with a notable increase of 2627.32% in holdings of Ailis [6]. - Ge Lan emphasizes that innovation, consumption recovery, and domestic substitution will drive the pharmaceutical industry in the second half of 2025 [6]. Group 4: Fu Pengbo's Approach - Fu Pengbo's Ruiyuan Growth Value Fund has a year-to-date return of 48.50%, focusing on high-growth companies [7][8]. - The fund has significantly increased its holdings in Alibaba and BYD by 161.10% and 184.78%, respectively [8][9]. - Fu Pengbo plans to continue focusing on sectors such as electronics, internet technology, and precision manufacturing, while also adapting to market volatility [9].

证券代码：688578 证券简称：艾力斯 公告编号：2025-020 股东上海艾祥企业发展中心（有限合伙）、南通艾耘企业发展中心（有限合伙）及 其一致行动人杜锦豪、上海乔可企业发展有限公司、JEFFREY YANG GUO 及 JENNIFER GUO 保证向上海艾力斯医药科技股份有限公司提供的信息真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 53.05% | | | | 权益变动后合计比例 | 51.87% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 投资者及其一致行动人的身份 控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人 ...